


What is claimed is:

1. A compound of Formula (I):



5 wherein:


R_3 is a monocycle selected from the group consisting of C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

10 R_4 is a moiety selected from the group consisting of C_2-C_{14} alkyl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, wherein R_4 is unsubstituted or substituted with 1 to 4 R_{10} groups;

15 R_5 is a moiety selected from the group consisting of hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxy, acyl, amide and nitro;

R_5' and R_5'' are independently selected from hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxy, acyl, amide, amino, acetamido and nitro;

20 R_6 is a group selected from the following formulae:



wherein:


25 R_8 is hydrogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxy;

R_8' is an C_3-C_{14} alkyl, 2 to 9 membered heteroalkyl, acyl, C_1-C_3 alkyl-nitrile, C_1-C_3 alkyl-carboxamide, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxy.

- 162 -

C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form an unsubstituted or substituted C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not

5




wherein R_6 is unsubstituted or substituted with 1 to 4 R_{10} groups;

10

R_9 is hydrogen, or a moiety selected from the group consisting of an C_1-C_9 alkyl, C_2-C_9 alkenyl, 2-9 membered heteroalkenyl, C_1C_9 alkylamide, C_1-C_9 alkyl-carboxamide, 2-9 membered heteroalkyl, C_1-C_4 alkyl-cycloalkyl, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not

15



and wherein R_9 is unsubstituted or substituted with 1 to 4 R_{10} groups;

20

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxy, acyl, amide and nitro;

25


wherein each R_{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1-C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_l(C_3-C_{10}$ cycloalkyl), $-(CR_dR_e)_l(aryl)$, $-(CR_dR_e)_l(4-10$ membered heterocycloalkyl), $-(CR_dR_e)_l(4-10$ membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_l(C_3-C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_l(aryl)$, $-(CR_dR_e)_qC(O)(CR_dR_e)_l(4-10$

- 163 -

membered heterocycloalkyl), -(CR_dR_e)_qC(O)(CR_dR_e)_t(4-10 membered heteroaryl),
-(CR_dR_e)_lO(CR_dR_e)_q(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_lO(CR_dR_e)_q(aryl),
-(CR_dR_e)_lO(CR_dR_e)_q(4-10 membered heterocycloalkyl),
5 -(CR_dR_e)_lO(CR_dR_e)_q(4-10 membered heteroaryl),
-(CR_dR_e)_qSO₂(CR_dR_e)_t(C₃-C₁₀ cycloalkyl),
-(CR_dR_e)_qSO₂(CR_dR_e)_t(aryl), and -(CR_dR_e)_qSO₂(CR_dR_e)_t(4-10 membered
10 membered heterocycloalkyl), -(CR_dR_e)_qSO₂(CR_dR_e)_t(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo,
hydroxyl, -NR_dR_e C₁-C₆ alkyl, trifluoromethyl, C₁-C₆ alkoxy, and trifluoromethoxy, R_b and R_c are independently selected from H, C₁-C₆ alkyl, -(CR_dR_e)_l(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_l(aryl), -(CR_dR_e)_l(4-10 membered
15 heterocycloalkyl), and -(CR_dR_e)_l(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C₁-C₆ alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R₁₀ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R₁₀ groups are unsubstituted or
20 substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR_b, -C(O)R_b, -C(O)OR_b, -NR_bC(O)R_c, -C(O)NR_bR_c, -NR_bR_c, -NR_bOR_c, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -(CR_dR_e)_l(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_l(aryl), -(CR_dR_e)_l(4-10 membered heterocycloalkyl), and
25 -(CR_dR_e)_l(4-10 membered heteroaryl);
and wherein any of the above-mentioned substituents comprising a CH₃ (methyl), CH₂ (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO₂ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C₁-C₄ alkyl, C₁-C₄ alkoxy and -NR_dR_e wherein R_d and R_e are as defined above;
30 or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

- 164 -

2. A compound of Formula (II):




wherein:

5 R_4 is a moiety selected from the group consisting of C_2-C_{14} alkyl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, wherein R_4 is unsubstituted or substituted with 1 to 4 R_{10} groups;

10 R_5 is a moiety selected from the group consisting of hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxy, acyl, amide and nitro;

15 R_5' and R_5'' are independently selected from hydrogen, hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxy, acyl, amide, amino, acetamido and nitro;

20 R_6 is a group selected from the following formulae:




wherein:

25 R_8 is hydrogen, C_{1-3} alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxy;


20 R_8 is an C_3-C_{14} alkyl, 2-9 membered heteroalkyl, acyl, C_1-C_3 alkyl-nitrile, C_1-C_3 alkyl-carboxamide, C_1-C_4 alkyl-heterocycloalkyl, C_1-C_4 alkyl-aryl, C_1-C_4 alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form a C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not

- 165 -



, and wherein R₈ is unsubstituted or substituted with 1 to 4 R₁₀ groups;

R₉ is hydrogen, or a moiety selected from the group consisting of an C₁-C₉ alkyl, C₂-C₉ alkenyl, 2-9 membered heteroalkenyl, C₁-C₉ alkylamide, C₁-C₉ alkyl-carboxamide, 2-9 membered heteroalkyl, C₁-C₄ alkyl-cycloalkyl, C₁-C₄ alkyl-heterocycloalkyl, C₁-C₄ alkyl-aryl, C₁-C₄ alkyl-heteroaryl, C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R₆ is not



10 , wherein R₉ is unsubstituted or substituted with 1 to 4 R₁₀ groups;

R₇ is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C₁-C₁₄ alkyl, C₁-C₁₄ alkoxy, acyl, amide and nitro;

15 wherein each R₁₀ is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C₁-C₆ alkoxy, C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -C(O)R_a, -C(O)OR_b, -OC(O)R_b, -NR_bC(O)R_c, -C(O)NR_bR_c, -NR_bOR_c, -S(O)_j(C₁-C₆ alkyl) wherein j is an integer from 0 to 2, -(CR_dR_e)_i(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_i(aryl), -(CR_dR_e)_i(4-10 membered heterocycloalkyl), -(CR_dR_e)_i(4-10 membered heteroaryl), -(CR_dR_e)_qC(O)(CR_dR_e)_i(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_qC(O)(CR_dR_e)_i(aryl), -(CR_dR_e)_qC(O)(CR_dR_e)_i(4-10 membered heterocycloalkyl), -(CR_dR_e)_qC(O)(CR_dR_e)_i(4-10 membered heteroaryl),

20 -(CR_dR_e)_iO(CR_dR_e)_q(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_iO(CR_dR_e)_q(aryl), -(CR_dR_e)_iO(CR_dR_e)_q(4-10 membered heterocycloalkyl), -(CR_dR_e)_iO(CR_dR_e)_q(4-10 membered heteroaryl), -(CR_dR_e)_qSO₂(CR_dR_e)_i(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_qSO₂(CR_dR_e)_i(aryl), and -(CR_dR_e)_qSO₂(CR_dR_e)_i(4-10

- 166 -

membered heterocycloalkyl), -(CR_dR_e)_qSO₂(CR_dR_e),(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, -NR_dR_e C₁-C₆ alkyl, trifluoromethyl, C₁-C₆ alkoxy, and trifluoromethoxy, R_b and R_c are independently selected from H, C₁-C₆ alkyl, -(CR_dR_e)(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_t(aryl), -(CR_dR_e)_t(4-10 membered heterocycloalkyl), and

-(CR_dR_e)(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C₁-C₆ alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R₁₀ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R₁₀ groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR_b, -C(O)R_b, -C(O)OR_b, -NR_bC(O)R_c, -C(O)NR_bR_c, -NR_bR_c, -NR_bOR_c, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -(CR_dR_e)_t(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_t(aryl), -(CR_dR_e)_t(4-10 membered heterocycloalkyl), and

-(CR_dR_e)_t(4-10 membered heteroaryl);

wherein any of the above-mentioned substituents comprising a CH₃ (methyl), CH₂ (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO₂ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C₁-C₄ alkyl, C₁-C₄ alkoxy and -NR_dR_e wherein R_d and R_e are as defined above;

and wherein Ph means phenyl;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

3. A compound according to Claim 1 wherein R₄ is a phenyl;
R₃ is a moncycle selected from the group consisting of C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;


- 167 -

R_5 is a moiety selected from the group consisting of hydroxyl, halo, C₁-C₁₄ alkyl, C₁-C₁₄ alkoxy, acyl, amide and nitro;

R_5' and R_5'' are independently selected from hydrogen, hydroxyl, halo, C₁-C₁₄ alkyl, C₁-C₁₄ alkoxy, acyl, amide, amino, acetamido and nitro;

5

R_6 is a group selected from the following formulae:




wherein:

10 R_8 is hydrogen, C₁-C₃ alkyl, C₃-C₁₀ cycloalkyl, or C₁-C₁₄ alkoxy;

15 R_8' is an C₃-C₁₄ alkyl, 2-9 membered heteroalkyl, acyl, C₁-C₃ alkyl-nitrile, C₁-C₃ alkyl-carboxamide, C₁-C₄ alkyl-heterocycloalkyl, C₁-C₄ alkyl-aryl, C₁-C₄ alkyl-heteroaryl, C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form a C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that R_6 is not

15




20

unsubstituted or substituted with 1 to 4 R_{10} groups;

R_9 is hydrogen, or a moiety selected from the group consisting of an C₁-C₉ alkyl, C₂-C₉ alkenyl, 2-9 membered heteroalkenyl, C₁-C₉ alkylamide, C₁-C₉ alkyl-carboxamide, 2-9 membered heteroalkyl, C₁-C₄ alkyl-cycloalkyl, C₁-C₄ alkyl-heterocycloalkyl, C₁-C₄ alkyl-aryl, C₁-C₄ alkyl-heteroaryl, C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not

25

- 168 -



unsubstituted or substituted with 1 to 4 R₁₀ groups;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxy, acyl, amide and nitro.

5 and nitro;

wherein each R_{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C_1 - C_6 alkoxy, C_1 - C_{10} alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1$ - C_{10} alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)(C_3$ - C_{10} cycloalkyl), $-(CR_dR_e)_q(aryl)$, $-(CR_dR_e)_q(4$ -10 membered heterocycloalkyl), $(CR_dR_e)(4$ -10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(C_3$ - C_{10} cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(aryl)$, $-(CR_dR_e)_qC(O)(CR_dR_e)_t(4$ -10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(4$ -10 membered heteroaryl),

$-(CR_dR_e)_qO(CR_dR_e)_q(C_3$ - C_{10} cycloalkyl), $-(CR_dR_e)_qO(CR_dR_e)_q(aryl)$, $-(CR_dR_e)_qO(CR_dR_e)_q(4$ -10 membered heterocycloalkyl), $-(CR_dR_e)_qO(CR_dR_e)_q(4$ -10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(C_3$ - C_{10} cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(aryl)$, and $-(CR_dR_e)_qSO_2(CR_dR_e)_t(4$ -10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(4$ -10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ C_1 - C_6 alkyl, trifluoromethyl, C_1 - C_6 alkoxy, and trifluoromethoxy, R_b and R_c are independently selected from H, C_1 - C_6 alkyl, $-(CR_dR_e)(C_3$ - C_{10} cycloalkyl), $-(CR_dR_e)_t(aryl)$, $-(CR_dR_e)_t(4$ -10 membered heterocycloalkyl), and $-(CR_dR_e)_t(4$ -10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C_1 - C_6 alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R_{10} groups are unsubstituted or substituted with 1 to 3 substituents.

- 169 -

independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR_b, -C(O)R_b, -C(O)OR_b, -NR_bC(O)R_c, -C(O)NR_bR_c, -NR_bR_c, -NR_bOR_c, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -(CR_dR_e)(C₃-C₁₀ cycloalkyl), -(CR_dR_e)(aryl), -(CR_dR_e)(4-10 membered heterocycloalkyl), and

-(CR_dR_e)(4-10 membered heteroaryl);

5


and wherein any of the above-mentioned substituents comprising a CH₃ (methyl), CH₂ (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO₂ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C₁-C₄ alkyl, C₁-C₄ alkoxy and -NR_dR_e wherein R_d and R_e are as defined above;

10

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

15

4. A compound of Formula (IV):



20

wherein:

R₃ is a monocycle selected from the group consisting of C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

25

R₄ is a moiety selected from the group consisting of substituted or unsubstituted C₂-C₁₄ alkyl, C₃-C₁₀ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

R₅ is a moiety selected from the group consisting of hydroxyl, halo, C₁-C₁₄ alkyl, C₁-C₁₄ alkoxy, acyl, amide and nitro;


- 170 -

R_5' and R_5'' are independently selected from hydrogen, hydroxyl, halo, C_{1-14} alkyl, C_1-C_{14} alkoxy, acyl, amide, amino, acetamido and nitro;

5 R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxy, acyl, amide and nitro;


R_8 is hydrogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, or C_1-C_{14} alkoxy;

10 R_8' is an C_{3-14} alkyl, 2-9 membered heteroalkyl, acyl, C_{1-3} alkyl-nitrile, C_{1-3} alkyl-carboxamide, C_{1-4} alkyl-heterocycloalkyl, C_{1-4} alkyl-aryl, C_{1-4} alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with R_8 cyclizes to form a C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-15 membered heteroaryl, with the proviso that R_6 is not



15 unsubstituted or substituted with 1 to 4 R_{10} groups;

20 R_9 is hydrogen, or a moiety selected from the group consisting of an C_{1-9} alkyl, C_{2-9} alkenyl, 2-9 membered heteroalkenyl, C_{1-9} alkylamide, C_{1-9} alkyl-carboxamide, 2-9 membered heteroalkyl, C_{1-4} alkyl-cycloalkyl, C_{1-4} alkyl-heterocycloalkyl, C_{1-4} alkyl-aryl, C_{1-4} alkyl-heteroaryl, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that R_6 is not



25 25 , wherein R_9 is unsubstituted or substituted with 1 to 4 R_{10} groups;

R_7 is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_{14} alkyl, C_1-C_{14} alkoxy, acyl, amide and nitro;

wherein each R₁₀ is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, C₁-C₆ alkoxy, C₁-C₁₀ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -C(O)R_a, -C(O)OR_b, -OC(O)R_b, -NR_bC(O)R_c, -C(O)NR_bR_c, -NR_bR_c, -NR_bOR_c, -S(O)_j(C₁-C₆)alkyl) wherein j is an integer from 0 to 2, -(CR_dR_e)(C₃-C₁₀ cycloalkyl), -(CR_dR_e)(aryl), -(CR_dR_e)(4-10 membered heterocycloalkyl), -(CR_dR_e)(4-10 membered heteroaryl), -(CR_dR_e)_qC(O)(CR_dR_e)_t(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_qC(O)(CR_dR_e)_t(aryl), -(CR_dR_e)_qC(O)(CR_dR_e)_t(4-10 membered heterocycloalkyl), -(CR_dR_e)_qC(O)(CR_dR_e)_t(4-10 membered heteroaryl),

-(CR_dR_e)_tO(CR_dR_e)_q(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_tO(CR_dR_e)_q(aryl), -(CR_dR_e)_tO(CR_dR_e)_q(4-10 membered heterocycloalkyl), -(CR_dR_e)_tO(CR_dR_e)_q(4-10 membered heteroaryl),

-(CR_dR_e)_qSO₂(CR_dR_e)_t(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_qSO₂(CR_dR_e)_t(aryl), and -(CR_dR_e)_qSO₂(CR_dR_e)_t(4-10 membered heterocycloalkyl), -(CR_dR_e)_qSO₂(CR_dR_e)_t(4-10 membered heteroaryl), wherein R_a is selected from the group consisting of halo, hydroxyl, -NR_dR_e, C₁-C₆ alkyl, trifluoromethyl, C₁-C₆ alkoxy, and trifluoromethoxy, R_b and R_c are independently selected from H, C₁-C₆ alkyl, -(CR_dR_e)_t(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_t(aryl), -(CR_dR_e)_t(4-10 membered heterocycloalkyl), and -(CR_dR_e)_t(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, R_d and R_e are independently H or C₁-C₆ alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing R₁₀ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing R₁₀ groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR_b, -C(O)R_b, -C(O)OR_b, -NR_bC(O)R_c, -C(O)NR_bR_c, -NR_bR_c, -NR_bOR_c, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -(CR_dR_e)_t(C₃-C₁₀ cycloalkyl), -(CR_dR_e)_t(aryl), -(CR_dR_e)_t(4-10 membered heterocycloalkyl), and -(CR_dR_e)_t(4-10 membered heteroaryl);

- 172 -


and wherein any of the above-mentioned substituents comprising a CH₃ (methyl), CH₂ (methylene), or CH(methane) group which is not attached to a halogeno, SO or SO₂ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, C₁-C₄ alkyl, C₁-C₄ alkoxy and -NR_dR_e wherein R_d and R_e are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.


10

5. A compound according to Claim 1 having the structure:


15




- 173 -



- 174 -



- 175 -



5

and multimers, pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.

10

6. A pharmaceutical composition comprising an effective amount of an agent to inhibit cellular proliferation and a pharmaceutically acceptable carrier, said agent being selected from the group consisting of compounds, multimers, pharmaceutically acceptable salts, prodrugs, and active metabolites as defined in any of claims 1, 2, 3, and 4.

15

7. A method of inhibiting a CDK selected from CDK2, CDK4, CDK6 or CDK complex, comprising administering an effective amount of a compound, multimer, pharmaceutically acceptable salt, prodrug, or active metabolite as defined in any of claims 1, 2, 3, and 4.

20

- 176 -

8. A method of treating cellular proliferative diseases, comprising administering an effective amount of a compound, multimer, pharmaceutically acceptable salt, prodrug, or active metabolite as defined in any of claims 1, 2, 3 and 4.

5

9. A method according to claim 8, wherein the disease is cancer, autoimmune disease, viral disease, fungal disease, neurodegenerative disorder or cardiovascular disease.

10

15

20

25

30

35